(Q52889176)

9 May 2018

title

Depression in Parkinson's Disease. (English)

1 reference

9 May 2018

1 reference

Richard IH

1

1 reference

9 May 2018

publication date

1 May 2000

1 reference

9 May 2018

Current treatment options in neurology

published in

1 reference

9 May 2018

volume

2

1 reference

9 May 2018

issue

3

1 reference

9 May 2018

page(s)

263-274

1 reference

9 May 2018

https://scigraph.springernature.com/pub.10.1007/s11940-000-0008-z

exact match

0 references

cites work

An estimate of the incidence of depression in idiopathic Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-000-0008-Z

Treatment of depression in Parkinson's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-000-0008-Z

Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-000-0008-Z

21 January 2018

The serotonin syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS11940-000-0008-Z

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-000-0008-Z

Serotonergic dysfunction in depression associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-000-0008-Z

Increase of Parkinson disability after fluoxetine medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-000-0008-Z

Bupropion in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-000-0008-Z

Transcranial magnetic stimulation: a neuropsychiatric tool for the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-000-0008-Z

Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-000-0008-Z

Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series

21 January 2018

1 reference

12 December 2020

Desipramine in treatment of Parkinson's disease. A placebo-controlled study

1 reference

12 December 2020

Moclobemide and selegeline in the treatment of depression in Parkinson's disease

1 reference

12 December 2020

Fluoxetine and extrapyramidal side effects

1 reference

12 December 2020

Does fluoxetine exacerbate Parkinson's disease?

1 reference

12 December 2020

Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers

1 reference

12 December 2020

1 reference

12 December 2020

A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group

1 reference

12 December 2020

Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?

1 reference

12 December 2020

Fluoxetine and selegiline--lack of significant interaction

1 reference

12 December 2020

Sertraline for the treatment of depression in Parkinson's disease.

1 reference

12 December 2020

1 reference

12 December 2020

Improvement in Parkinsonian symptoms after repetitive transcranial magnetic stimulation.

1 reference

12 December 2020

Treatment of depression in elderly patients: recent advances

1 reference

12 December 2020

IMIPRAMINE IN TREATMENT OF PARKINSONISM: A DOUBLE-BLIND PLACEBO STUDY

1 reference

12 December 2020

Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study.

1 reference

12 December 2020

Mood improvement from transcranial magnetic stimulation

1 reference

12 December 2020

Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA

1 reference

12 December 2020

Fluoxetine in Parkinson's disease

1 reference

12 December 2020

Lack of adverse interactions between concomitantly administered selegiline and citalopram

1 reference

12 December 2020

Using interpersonal psychotherapy (IPT) in a combined psychotherapy/medication research protocol with depressed elders. A descriptive report with case vignettes.

1 reference

12 December 2020

Safety of transcranial magnetic stimulation in patients with implanted deep brain stimulators.

1 reference

12 December 2020

Possible use of amantadine in depression

1 reference

12 December 2020

Repetitive transcranial magnetic stimulation has a beneficial effect on bradykinesia in Parkinson's disease

1 reference

12 December 2020

Interaction of fluoxetine and selegiline

1 reference

12 December 2020

What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment

1 reference

12 December 2020

Does fluoxetine aggravate Parkinson's disease? A pilot prospective study

1 reference

12 December 2020

Experience with tranylcypromine in early Parkinson's disease

1 reference

12 December 2020

The correlation of depression with functional activity in Parkinson's disease

1 reference

12 December 2020

Parkinsonism exacerbated by paroxetine

1 reference

12 December 2020

10.1007/S11940-000-0008-Z

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018